Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Kindred Companion Sciences Unveils First Dogs Genetically Edited to Remove the Major Dog Allergen
SAFETY SHOT INC C/WTS 30/10/2025(TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 44.95 K
SAFETY SHOT INC C/WTS 30/10/2025(TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 42.1 K